A Clinical Registry of Spontaneous Intracranial Hypotension
Part of paid clinical trials in Rochester, Minnesota.
- Sponsor
- Mayo Clinic
- Study ID
- NCT05922514
- Status
- Recruiting
Conditions
- Spontaneous Intracranial Hypotension
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Transvenous Embolization of Cerebrospinal Fluid-Venous Fistula — PROCEDURETransvenous embolization of a cerebrospinal fluid-venous fistula performed via percutaneous venous access under fluoroscopic guidance. The procedure involves catheterization of the paraspinal or epidural venous system draining the fistula and delivery of an embolic agent to occlude the pathological venous outflow and eliminate CSF egress. The goal is to achieve durable fistula occlusion and resolution of spontaneous intracranial hypotension symptoms.
Study Details
The purpose of this research is to determine the efficacy of paraspinal vein embolization for treatment of digital subtraction myelography (DSM) or CT myelography (CTM) confirmed cerebrospinal fluid (CSF)-venous fistulas so that researchers can inform the development and design of future clinical trials of this technique.
Key Dates
- First listed
- Jun 28, 2023
- Start date
- Jun 18, 2023
- Status verified
- Aug 2026
- Primary completion
- Jul 31, 2028
- Completion
- Dec 31, 2028
Study Design
- Enrollment
- 400 participants (estimated)
Arms
- Arm: Group 1 Baseline, 3 months, 1 year, 1.5 years, and 2 years Questionnaires170 participants with BERN imaging score with completion of baseline, 3 months, 1 year, 1.5 years, and 2 years questionnaires being : headache impact test (HIT-6), migraine disability assessment test (MIDAS), pain numerical rating scale (NRS), and spontaneous intracranial hypotension symptom severity scale (SIHSS). Each participant will keep a daily headache diary for 90 days.
- Arm: Group 2 Baseline, 7 days and 3 month, 1 year, 1.5 years, and 2 years Questionnaires30 participants with BERN imaging score with completion of baseline, 7 days, 3 months, 1 year, 1.5 years, and 2 years questionnaires being : headache impact test (HIT-6), migraine disability assessment test (MIDAS), pain numerical rating scale (NRS), and spontaneous intracranial hypotension symptom severity scale (SIHSS). Each participant will keep a daily headache diary for 90 days.
Primary Outcome Measure
Change in Headache Impact Test (HIT-6) [ Time Frame: Baseline, 3 months, 1 year, 1.5 years, 2 years ]
Central Contacts
- Gerard El Hajj, M.D.507-255-2860
- Theresa Nielson507-422-0743
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic Minnesota | Rochester | Minnesota | 55905 |
Find similar trials in Rochester, MN
By research site
Related Studies
- CVFs in SIH: EID vs. PCD CTMRecruiting · Duke University · Durham, North Carolina